Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andexanet Alfa in Acute Intracranial Hemorrhage with FXa Inhibitors
NCT03661528Phase 4Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2019
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 24
01
Overview
A Phase 4 trial of andexanet alfa in acute intracranial hemorrhage (ICH), sponsored by Alexion Pharmaceuticals. Started Jun 2019; status: completed.
02
Drugs
andexanet alfa
03
Conditions
acute intracranial hemorrhage (ICH)
Beyond the preview
Go deeper on NCT03661528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03661528.